A  new  era,  new  vision  for  WuXi  and  NextCODE  Health    

Hannes  Smarason    Genome  Sequencing  |Personalized  Medicine  |  Transforming  Health  Care  

Our  Opportunity:  Enhance  Value  of  Genomics  in  Medicine  

In  the  fast-­‐paced  genomics  community,  we  con?nually  look  for  new  opportuni?es  and  strategies  to  enhance  the  value  of  genomics  and  use  the  increasingly  robust  body  of  genomic  data  for  the  advancement  of  clinical  medicine.    

We’re  excited  to  announce  a  new,  ambi?ous  vision  to  do  just  that,  with  WuXi’s  acquisi?on  of  NextCODE  Health.    

NextCODE  and  WuXi  

•  NextCODE  will  be  merged  with  WuXi’s  exis?ng  Genome  Center  in  wholly-­‐owned  subsidiary  called  WuXi  NextCODE  Genomics,  with  unique,  comprehensive  and  global  capabili?es  for  using  genomic  data  to  deliver  beOer  medicine  and  improve  healthcare.    

 

Increased  Value  Through  CollaboraIon  •  WuXi,  a  Shanghai-­‐based  genomic  laboratory  service  partner  for  companies  in  the  pharma  and  biotech  community,  has  already  been  collabora?ng  with  NextCODE  to  provide  analysis  services  to  customers  of  the  WuXi  Genome  Center.    

•  Now,  with  the  in-­‐house  capability  to  analyze,  store  and  manage  the  vast  amount  of  genomic  data,  NextCODE’s  industry  leading  genome  sequence  analysis  plaPorm  will  expand  WuXi’s  core  NGS  benefits  and  services.    

Enhancing  CapabiliIes  and  ContribuIons  

•  Pairing  WuXi’s  technology  and  exis?ng  reach  with  NextCODE’s  leading  analy?cs  and  database  promises  to  advance  the  pace  of  genomics  research  today.      

•  More  importantly,  however,  this  new  era  for  our  company  brings  exci?ng  opportuni?es  to  maximize  the  most  advanced  tools  available  today  and  contribute  to  major  advances  in  genomic  medicine.